0000000000274163
AUTHOR
E Di Martino
5PSQ-096 Hazard vulnerability analysis to evaluate the risk of drug shortages according to therapeutic class
Background and importance Drug shortages are a critical challenge for the public health system, as highlighted by EAHP’s position paper. They have a negative impact on quality and efficiency of patient care. Aim and objectives The aim of our study was the application of a revised hazard vulnerability analysis (HVA) to assess which therapeutic classes of drugs are at greatest risk of shortages. Material and methods In September 2019, we analysed the drugs present in our hospital therapeutic formulary and checked which ones were included in the Italian Medicines Agency shortages list: 43 drugs were found. For each drug, we assigned a score using a revised HVA which consists of three macro are…
2SPD-025 Application of hazard vulnerability analysis to evaluate the risk level of medicine shortages
Background and importance Drug shortages have become a worldwide phenomenon which has repercussions on patient care and on the hospital’s budget. Aim and objectives The aim of our study was to assess the risk of shortages of drugs included in our hospital therapeutic formulary (HTF), for which there is shortage reporting, using a hazard vulnerability analysis (HVA). Material and methods We performed an HVA on 43 drugs in our HTF, which were also included in the Italian Medicines Agency list of shortages. The HVA used to assign the risk of shortage (ROS) included three macro areas: probability that the shortages will occur based on shortages in the past 2 years; magnitude factors which incre…
5PSQ-100 Comparative analysis of the safety and tolerability profile of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis
Background and importance The main treatments for idiopathic pulmonary fibrosis are pirfenidone and nintedanib. Although their efficacy is known, further studies are needed to evaluate the safety and tolerability profiles (STPs) based on real world data. Aim and objectives The aim of this study was to evaluate the STP of nintedanib and pirfenidone according to our hospital data. Material and methods We analysed 148 patients treated with pirfenidone (72% men; 28% women) and 120 treated with nintedanib (77% men; 23% women) from September 2016 to September 2019. The average age of the patients treated with pirfenidone and nintedanib was 72.7 and 74.4 years, respectively. Drug tolerability was …